Interview with Milanese immunologist Attilio Speciani. They call it an anti-obesity drug, but it's not just that: in reality, the molecule opens up research into many other chronic pathologies, all those linked to excess glycation, from Alzheimer's to kidney failure to heart disease. And for…
Pharmaceutical industry giants Eli Lilly and Novo Nordisk have been among the hardest hit by the incredible market volatility. After the collapse of recent days, yesterday they achieved an impressive leap on the stock market
The Swiss pharmaceutical company exceeds expectations with an excellent second quarter. Net sales up 11%, core operating profit up 43%. Strong momentum across all segments, with innovations and expanding pipeline. The company revises upward…
Pharmaceuticals confirms itself as the second Made in Italy sector in terms of foreign balance, generating a value of 17 billion in 2023. Furthermore, the share of exports in total manufacturing has more than doubled in the last 20 years, going from 3,8% to 8,3%
US pharmaceutical and cosmetics giant J&J accepted this sum to settle investigations conducted in 42 US states and the District of Columbia. New York State will receive $44 million to be paid in…
Big maneuvers among the big American companies with M&A operations. Meanwhile, the Italian Recordati is thinking about targeted M&A operations in its new plan to 2025
Angelini had 0,47% of Mediobanca and 0,06% of Unicredit: small but significant shares. The already good financial situation of the multifaceted Italian group grows further. But what else will such abundant cash be used for?
The aging population is driving up sales of medicines for chronic diseases, while weight loss products will reach over 75 billion by 2030 and it is no coincidence that Novo Nordisk and Eli Lilly shine in…
Astrazeneca's aim is to strengthen itself in the field of innovative cell therapies for the treatment of cancer and autoimmune diseases
Acquired the entire research and development portfolio of the US company. Carmot is working on innovative treatments for obesity
The Swiss big pharma has announced investments in the country to strengthen the production lines, in particular at the Ivrea and Torre Annunziata sites. 100 hires are also expected
The proposed acquisition price, at $19 per share all cash, represents a premium of 82%
But costs threaten health care bills. And the Danish group has decided to curb production for now. Behind it presses the US competitor Eli Lilly
The Treasury's corrections to the tax on the extra profits of government banks have given impetus to credit stocks which, however, have only recovered half of the beating of Black Tuesday - Pharmaceutical stocks and the Danish Novo run…
The Angelini group closes 2022 with strongly growing revenues in all sectors of activity: Pharma, industrial technologies, consumption. Strengthening in brain health
Novartis, a Swiss pharmaceutical group, has reached an agreement to purchase the biopharmaceutical company Chinook Therapeutics, which specializes in drugs for kidney diseases
Revenues amount to 290 million euros. The reduction in margins is mainly a consequence of the lower Covid revenues. Guidance 2023 confirmed
The Treasury's intention to reduce its shareholding in Mps in view of a possible integration with Banco BPM sends the Sienese bank flying to Piazza Affari where instead pharmaceutical stocks suffer - Exchanges on standby in Europe…
Italy is the only one of the leaders in the agricultural machinery sector to lose market share in the last five years. Competition from Asia is increasingly fierce, exploiting above all the price lever.
The US pharmaceutical giant will pay $229 for each share in cash. And the titles fly to Wall Street
The cash portion represents approximately $1,3 billion in transaction value and a 121% premium. The maximum value of the acquisition with the potential exercise of the right would be $1,8 billion and would have a premium…
Global Blood Therapeutics stock has gained more than 90% of its value on the Nasdaq from Thursday to today
The deal also includes the investigational clinical-stage T-cell treatment, TNB-486, which strengthens the hematologic cancer pipeline.
Pfizer will pay $148,5 per share, all in cash. The closing is expected in the first months of 2023 - Biohaven shares fly to Wall Street and are close to the offer price
The French pharmaceutical company reaches 37,8 million in revenues in 2021, up by 7,1%. The sales of Dupixent (+52,7%) and vaccines (+6,8%) are the driving force
Net income fell 1%, while revenue climbed 8% - 2022 growth slower
The Friulian company has entered the private equity fund Ardian - This is the second investment in the pharmaceutical sector for the French group - Maurizio Castorina will remain at the helm of the company
Second day of rising for the Italian stock market in 2022 which in the end, however, suffers from the abrupt turnaround of American technology stocks while T-bonds break through 1,67% - Iveco rises again, the Agnelli-Elkann galaxy runs - Banks ok - Sales…
Swiss drugmaker continues its pharmaceutical buyouts - This time it's up to the British ocular gene therapy firm to speed up trials for the treatment of geographic atrophy, a leading cause of blindness
Ex-Covid turnover is expected to grow by 24% in 2022, total turnover down by 2% - Covid revenues down from 370 million in 2021 to 150 million in 2022 - New programs in immunodiagnostics kick off
We are talking about Arena Pharmaceuticals, whose shares will be purchased at 100 dollars each, with a 100,2% premium. It is the second maxi acquisition in the sector after that of Novartis at the end of November
Widespread sales on all stock markets after the recent rally - Pharma, Luxury and High Tech stocks among the hardest hits - Tim, best stock in the Ftse Mib, rebounds in Piazza Affari
The volatility induced by the new wave of Covid is returning to the markets even if encouraging signs are arriving from pharmaceutical companies and the disappointing sales of Iphones penalize Apple and all high tech - But the agreement on the increased production of oil matured…
Scientist Stéphane Bancel speaks and cools the enthusiasm of the markets: it will not be so easy to counter Omicron - more optimistic Pfizer with record turnover. But it is controversy with South Africa on the power of Big Pharma
Great leap on the stock market by Telecom Italia and pharmaceutical stocks but not enough to support the Ftse Mib, dominated by sales also due to the fear of the resurgent pandemic
One company will sell over-the-counter drugs and have a new name - The other, which will keep the old brand name, will focus on pharmaceuticals and advanced research medical devices
The American Big Pharma, with the collaboration of BioNTech, collects the extraordinary result of the best-selling vaccine in the history of medicine. Logistics and science are the basis of the resounding success. US green light for vaccination for children aged 5-11
Kadmon shareholders to receive $9,5 per share, a 79% premium over Monday's stock close - Sanofi drug portfolio Rezurock immediately
Selling day on all European stock exchanges and partly on Wall Street - The drop in business confidence in Germany also weighs - Sharp decline in Piazza Affari, where pharmaceutical stocks suffer above all
A sensational sentence, a 4,5 billion indemnity to compensate half a million victims: the Sacklers lose Purdue Pharma but are saved from the most serious accusations about the killer drug. Here's what happened
After last Friday's sensational surge in the stock market, yesterday the shares of the two pharmaceutical companies collapsed under the ax of a devastating report by Bofa which defines their valuations as "ridiculous" - In reality, behind the business of…
For US Pharma, record profits driven by vaccines against the pandemic. For Moderna doubled quarterly profit and for Pfizer a turnover of 33,5 billion is looming at the end of the year. And the second quarter promises to be even richer
The pharmaceutical group saw its profits fall due to depreciation and higher taxes. 92 million euros invested in research and development
In the race for the listing, Aim, beacon on Ulisse BioMed and Compagnia dei Caribbean making their debut in the segment of small and medium-sized enterprises. Here are their stories
After the transfer of Altavilla to Ita, the pharmaceutical company reorganizes its Governance - From 1 December Koremans will become CEO, working in continuity with the past, while the current CEO Andrea Recordati will cover the position of president
Little moved Wall Street does not awaken the European stock exchanges which close down in view of the Fed and in the wake of fears about infections in India. Milan flat, oil companies down - Waiting for Atlantia's board of directors scheduled…
The green light from the German Constitutional Court does not restore impetus to the stock exchanges, waiting for the ECB - But pharmaceutical stocks are recovering and Diasorin presents a test capable of detecting Lyme disease in ten minutes
The billionaire conquest of the American Luminex gives wings to Diasorin which gains 9,63% in a single day - Asset management is also doing well - Sales on Stm - The Ftse Mib reaches 24.457 basis points
Patent protection systems need to be reordered: monopoly positions need to be broken and Biden's proposals go in that direction - Big Pharma is the most hated industry, but it was able to find the anti-Covid vaccine in…
Results from the Roche Group's phase III trial, conducted in infected but not hospitalized patients, showed that the cocktail of casirivimab and imdevimab significantly reduces the risk of hospitalization or death.
The race for vaccines has highlighted the clear supremacy of the American pharmaceutical industry over the European one. But where does the weakness of our industry come from? There are at least three reasons for the gap
The 90-year-old financier is increasingly focusing on health: in addition to Pfizer, he has entered the capital of AbbVie, Bristol-Myers Squibb and Merck. And as a result he "abandons" the banks...
The improvement in Trump's health and the rise in oil prices invigorate the stock markets - Poste Italiane exploits Piazza Affari and excellent performance also by pharmaceutical stocks - Two gold strikes for Nexi…
The hope of the anti-Covid vaccine supports the stock exchanges on the day when the epidemic reaches its peak worldwide - The restart of AstraZeneca gives confidence - Meanwhile Softbank, under accusation for derivatives on high tech, sells Arm Holdings…
Johnson & Johnson to disburse $6,5 billion in cash - Goal is to expand into autoimmune disease treatments
After gold, silver is also increasingly on the rise - Stock exchanges in contrast - Piazza Affari slightly down despite the sharp rise in pharmaceutical stocks: it is the banks and utilities that are pushing downwards
French giant to buy all outstanding shares of Principia for $100 a share, a 10% premium to the stock's August 14 price
The photographic film company, given up for dead, instead resurrects and launches into the pharmaceutical business - Sensational leap on Wall Street - Its mission will now be to produce generic drugs thanks also to a substantial government funding for…
The pet economy is increasingly attractive for medicine manufacturers and for the asset management industry which is driving investments in veterinary healthcare. With excellent returns on capital for shareholders
The CEO of AbbVie Italia has been confirmed for another two years at the top of the Italian American Pharmaceutical Group
The Tuscan group bought the US company that develops oncological therapies at a price of 677 million dollars - Stemline +152% on the Nasdaq
The new environmental regulations increase the costs for chemistry, while the pharmaceutical industry moves more and more to India and China – But Made in Italy resists: the 3,6 billion turnover represents 9% of the world market…
In October, the increase in exports is attributable to the growth trend in sales to non-EU markets (+6,1%), while demand from EU countries is weak, especially in Germany (+0,2%) - Excellent the performance (+10-20%) in Japan, Switzerland and the USA
The French giant bought the Californian Synthorx for 2,5 billion dollars, more than double the stock market value - The goal is to expand into the innovative cancer treatments sector
Stock exchanges without direction and Piazza Affari on parity - Together with the pharmaceuticals Italgas and Azimut do well - Sales on Campari, Moncler, CNH and Exor.
The value of exports in the first five months of 2019 increased by 4%, followed by a slight decrease in June (-0,9%) offset by the increase in average unit values (+3,6%). If the so-called pre-Brexit “inventory effect” continues to support sales to…
Founded as a spin-off of the University of Brescia and listed on the AIM segment of the Italian Stock Exchange, the Brescia-based company has become an international leader in visual inspection, product tracking and data management systems for the pharmaceutical sector.
The agreement provides that Mediolanum Farmaceutici will remain a shareholder of Neopharmed Gentili with a minority stake. Alessandro Del Bono will hold the role of president and chief executive officer of the company.
Development contract with 5 companies from Campania for the industrial development of the pharmaceutical sector. An R&D project with local universities is also planned.
The pharmaceutical company, a jewel of Made in Italy, has reached an agreement with the British private equity fund but the Recordati family will also remain involved in the new management. Andrea will remain CEO Discount takeover bid: 28 euros against 34,6 at the closing…
From June 7 Monsanto brand will disappear and its products will be sold only under their trademark - One of the biggest mergers in recent years completed - Bayer expects positive contribution to basic earnings per share…
The company sold its 36,5% stake in the Consumer Healthcare joint venture, which deals in non-prescription drugs, including popular and commonly used products, to GlaxoSmithKline
It is the largest foreign acquisition ever made by a Japanese company - After this operation, which has yet to receive the go-ahead from the shareholders' meetings of the two companies, the Japanese giant could become the ninth largest group in the world in terms of…
This is the second major acquisition in a row for the French giant, which a few days ago had already acquired the American Bioverativ - The group will continue to evaluate acquisitions "case by case".
Kite Pharma shares fly to Wall Street, gaining 29% - Gilead will pay a price (in cash) equal to $180 per share.
From ATLANTE PROMETEIA - The pharmaceutical sector is the only Italian manufacturing sector characterized by activity levels above the pre-crisis level. The growth, supported by the lively expansion of sales abroad, is widespread in all size classes and has allowed our…
The Swiss pharmaceutical company recorded a net result down to 2,87 billion dollars against the previous 2,93 billion,
In the first quarter, the German giant saw profits grow by 38%, to 2,1 billion euros, a result that allows it to raise its estimates for the entire year - The Swiss group, on the other hand, recorded a turnover higher than forecasts…
Mega operation in the pharmaceutical chemical: the acquisition makes the European stock exchanges shine. Strong prize awarded to shareholders
AstraZeneca could collect up to 1,6 billion dollars from the operation, also thanks to the rights to the drugs involved
INTERVIEW OF THE WEEKEND - Francesco Di Marco, CEO for Italy of Amgen, talks about the new frontiers of pharmaceuticals
The American pharmaceutical giant does not expect an impact of the transaction on its 2016 accounts but expects it to be slightly dilutive of the adjusted earnings per share (eps) in 2017 with growth in EPS starting in 2018 and increasing in subsequent years.
AstraZeneca will immediately pay 2,5 billion dollars for the 55% Acerta Pharma stake, while the remainder will be paid after the US authorities allow the new drug to be tested by 2018.
The merger should be completed in the second half of 2016 - The agreement will bring tax advantages for the US company given that the company's headquarters should be in Ireland.
According to a study by Crea Sanità, which takes into consideration the case of the Norvatis group, the pharmaceutical industry can become a resource for public finances, guaranteeing savings and investments in research and development at the same time.
The headquarters and headquarters of the leading group of the Swiss pharmaceutical industry will remain in Basel despite the strength of the franc which reduces competitiveness and despite the popular vote against mass immigration: the president Jorg Reinhardt specified…
FOCUS BNL - While the capital is experiencing one of its most difficult moments amidst corruption, chaos and degradation, shoots of recovery are emerging in Lazio: 180 billion euros of GDP, equal to 10% of Italy's GDP and as much as the whole of Greece…
The transaction will be concluded after the authorization of the Antitrust - In 2014 Doppel achieved net revenues of approximately 83,4 million euros
According to the annual report of Farmindustria, all the indicators of the sector are growing - In the last 12 months, 5.000 hires, also thanks to the Jobs Act - Investments +11% over the year, production +4,5% to 28,7 billion euros, exports…
The Israeli giant, which operates in 60 countries around the world and has over 46.000 employees, has offered $82 per share, half in cash and half in shares, to win over the American company.
The slow process of reform and opening up of the economy continues. However, as reported by SACE, the base is still not very diversified with high default risks and currency availability, but with some opportunities ahead.
The Mps-Phd index elaborated by Banca Mps highlights the growth of the sector - But Italian health expenditure is lower than the European and US average - And the national network of pharmacies has 18 units out of 100 active in the EU.
At the end of the operation, which should be finalized by the end of April, the new company will have a record turnover of 900 million and will be owned 75% by the Golinelli family (Alfa Wassermann) and 20% by some members of the Cavazza family.
The biotech company AAA (Advanced Accelerator Applications) chaired by the financier Claudio Costamagna and of which Giovanni Tamburi is also a shareholder continues its shopping and buys the Atreus Pharmaceutical Corporation in Canada, a start-up from Ottawa - Possible…
Stefano Pessina, 73, CEO of Alliance Boots, has taken over from Greg Wasson at the helm of Walgreen.
Merck intends to pay 102 dollars for each Cubist share (a US group that produces antibiotics), or a 37% premium on the closing of shares on the Nasdaq last Friday (74,36 dollars).
MPS REPORT - Followed by textiles and leather, means of transport, paper and machinery - But in recent months the scenario may change.
Presented yesterday, the new DHL Supply Chain campus is an area of 92 square meters 25 km from Rome and will provide logistics for Italy's second largest pharmaceutical hub: "From here we expect 250 orders a year: throughout Italy we make 1,8 million, with…
